期刊
CANCER RESEARCH AND TREATMENT
卷 50, 期 4, 页码 1462-1466出版社
KOREAN CANCER ASSOCIATION
DOI: 10.4143/crt.2017.473
关键词
Refractory/relapse; B-cell lymphoma; Chimeric antigen receptor T cells; Terminal ileal perforation
类别
资金
- 973 Program [2015-CB964900]
- Natural Science Foundation of China [81230014, 81470341, 81500157, 81770201, 81730008]
- Key Project of Science and Technology Department of Zhejiang Province [2015C03G2010091]
Chimeric antigen receptor T-cell strategy targeting CD19 (CART19) has prominent anti-tumor effect for relapsed/refractory B-cell lymphomas. CART19-associated complications have been gradually recognized, however, late-onset complications have not been extensively studied. Herein, for the first time we report a diffuse large B-cell lymphoma patient with terminal ileum involvement obtained rapid remission and developed spontaneous terminal ileal perforation 38 days following CART19 infusion. The late-onset perforation reminds us that, for the safety of CART treatment, more cautions are warranted for the management of delayed GI complications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据